(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 236.83% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Ocugen's revenue in 2026 is $4,580,000.On average, 9 Wall Street analysts forecast OCGN's revenue for 2026 to be $1,510,397,726, with the lowest OCGN revenue forecast at $509,343,822, and the highest OCGN revenue forecast at $2,172,002,118. On average, 7 Wall Street analysts forecast OCGN's revenue for 2027 to be $3,811,261,797, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $12,603,038,053.
In 2028, OCGN is forecast to generate $72,352,595,157 in revenue, with the lowest revenue forecast at $4,586,129,063 and the highest revenue forecast at $144,756,056,875.